about
The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells.Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.Cytokines and VEGF induction in orthodontic movement in animal models.Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workersChlamydia trachomatis induces an upregulation of molecular biomarkers podoplanin, Wilms' tumour gene 1, osteopontin and inflammatory cytokines in human mesothelial cells.Translational Research and Plasma Proteomic in Cancer.Multifaceted Breast Cancer: The Molecular Connection With Obesity.The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.HPV epigenetic mechanisms related to Oropharyngeal and Cervix cancers.Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in diagnosis of pleural effusion of malignant origin.Molecular profile of sensitization in subjects with short occupational exposure to latex.pRb2/p130 localizes to the cytoplasm in diffuse gastric cancer.Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization.The p85 regulatory subunit of PI3K mediates cAMP-PKA and insulin biological effects on MCF-7 cell growth and motility.Prognostic implications of node metastatic features in OSCC: A retrospective study on 121 neck dissectionsBRAF mutation and RASSF1A expression in thyroid carcinoma of southern ItalyPrognostic significance of N-Cadherin expression in oral squamous cell carcinoma
P50
Q30009887-A11A1B5C-C10C-4CC3-BB5B-7D69BBF131C3Q35742519-35926699-BFD9-41A9-B93E-99BB7E942D12Q35991187-081BBBF0-C6BB-4645-87DB-AECD8372284BQ37631325-00686DB0-BB75-43EB-9467-9C760413EDAEQ37834100-614333C1-5FE1-407D-B1DA-F4275B7952D4Q38610869-08CD8873-2998-45D8-8DF1-CDBDC5991B45Q38882124-C5ECB6CA-745F-488D-BC77-31B6215C680CQ39055490-50F7DCBA-4E45-4A2E-8304-269BEA584FF0Q39210845-36B29BF3-CDA9-49B1-A233-E7072A54E87CQ40105778-F0E23DA8-4BAD-4AE9-BB6F-6232D5957157Q41532152-2524E89E-3B1A-4ADF-981D-72EF07F39EDEQ44407120-D9872D0D-D223-45B5-AD3D-C14759A081F2Q44661984-A8BE86C7-284B-4469-ACDE-AFA27BD989BAQ54331486-0DFDF06A-AB7A-4D5D-B013-91D7DC35F71BQ60229483-3CB62DD9-0B0A-4C68-A6E0-C4B59C0B08B8Q60590414-EBCABE55-E2C9-489A-90B5-591238663186Q83135320-240B7D31-12AD-4160-B3A5-2AD9572AC4C5
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-0436-4621
@en
name
Antonia Feola
@ast
Antonia Feola
@en
Antonia Feola
@es
Antonia Feola
@nl
type
label
Antonia Feola
@ast
Antonia Feola
@en
Antonia Feola
@es
Antonia Feola
@nl
prefLabel
Antonia Feola
@ast
Antonia Feola
@en
Antonia Feola
@es
Antonia Feola
@nl
P108
P106
P108
P21
P31
P496
0000-0003-0436-4621